ClinicalTrials.gg
Not yet recruitingNCT07247630Updated Feb 3, 2026

Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children

An Early Phase 1 interventional study of Permethrin 5% in Scabies, sponsored by College of Physicians and Surgeons Pakistan. Not yet recruiting at 1 site in Pakistan. Open to participants aged 1 Month to 4 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by College of Physicians and Surgeons Pakistan · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Early Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
1 Month to 4 Years
Sex
All
01

Study summary

To compare the efficacy of different permethrin-based therapies for scabies infestations in infants and young children.

Read the detailed description

Globally, Scabies infects 300 million people each year and among children of developing countries, its prevalence is estimated to be about 5-10%.In Pakistan, Scabies accounts for 38% of dermatological diseases. Males are more prone to infestation than females, and early school- aged children are the most vulnerable as it is usually transmitted by prolonged skin-skin contact.

It was more widespread in urban than in rural areas with a distinct seasonal pattern, with the biggest infestation occurring in the winter and the lowest in the summer with all risk factors accounting for 89% of the variation in its prevalence.The classic scabies symptoms include an erythematous papular eruption, burrows, and intense itching with a predilection for fingers, axilla, elbows, waist, belly, groin, genital area, etc. Several antiscabietic treatment options exist, including topically applied permethrin, benzyl benzoate (BB) and crotamiton, and oral ivermectin.5 Repeated administration of topical permethrin 5%, topical BB 10-25% or systemic ivermectin dosed at 200 μg/kg body weight is currently recommended as first-line treatment by the 2017 European guidelines for the management of scabies.Permethrin, a synthetic pyrethroid with scabicidal and ovicidal activity, disrupts the function of the voltage-gated sodium channels in the neuronal membrane of the mites, resulting in paralysis and death. Permethrin is highly effective against scabies and well- tolerated without major side-effects, as it is minimally absorbed through the skin and rapidly eliminated, thus exerting minimal systemic presence in humans.Hence, it is recommended as a first-line therapy for adults and children in many countries

02

Conditions studied

  • Scabies

Browse trials for

Keywords

  • Permethrin based treatment strategies
03

In context

Scabies

51 studies on the registry are indexed under Scabies; 10 are open to participants now.

This study's planned enrollment of 68 is below the median of 183 across 41 interventional studies indexed under Scabies.

Browse Scabies studies →

Lead sponsor

College of Physicians and Surgeons Pakistan is the lead sponsor of 15 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 month to 4 years age.
  • Both gender
  • Scabies as defined in operational definition

Exclusion criteria

Exclusion Criteria:

    • Drug sensitivity test results for to permethrin

      • Having renal or hepatic impairment.
      • Individuals with additional long-term skin and systemic disorders (such as diabetes, hypertension, asthma, epilepsy, acne, psoriasis)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    Standard permethrin treatment

    Standard permethrin treatment

    Drug: Permethrin 5%

  • Active comparator
    Intensified permethrin treatment

    Intensified permethrin treatment

    Drug: Permethrin 5%

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment of scabies

    For efficacy, we will see microscopy (presence of any one by examine skin scraping under a microscope for mites(eyeless and spherical in shape with eight legs parasite)/eggs (oval shape).The absence of these will be considered significant.

    Time frame: 15 days

Secondary outcomes

  1. Scabies

    Absence of burrows on skin

    Time frame: 15 days

  2. Scabies

    Absence of pruritus

    Time frame: 15 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247630
Lead sponsor
College of Physicians and Surgeons Pakistan
Responsible party
Shanza zafar (Doctor, Pak Emirates Military Hospital) — Principal investigator
First posted
Nov 25, 2025
Start date
Jan 15, 2026 (estimated)
Primary completion
Mar 15, 2026 (estimated)
Completion
Jun 15, 2026 (estimated)
Last update
Feb 3, 2026

Study contacts

Shanza zafar, MBBs
Contact
shanza444@gmail.com
+923425316096

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Permethrin

Start the discussion